Sponsored by
This signal concerning proton pump inhibitors (PPIs) first emerged from analyses of real-world registry data from the xCures database, which suggested a potential link between PPI use and shorter survival in glioblastoma (GBM) patients. It is a good example of how patient registries and real-world evidence can help identify clinically relevant signals early, often years before they are evaluated or confirmed in larger randomized clinical trial datasets. Now, the association has been independently validated in a large analysis of nearly 3,000 patients from five randomized GBM clinical trials.
The recent study found that patients taking certain PPIs, including omeprazole and pantoprazole, had shorter progression-free and overall survival, even after adjusting for key factors such as age, MGMT status, extent of surgery, and steroid use. Other stomach-protecting medications, such as famotidine (Pepcid), did not show the same association, suggesting the effect may not simply be related to acid suppression.
This does not prove that PPIs cause worse outcomes, but the consistency of the signal across datasets adds to the concern. Since many GBM patients are placed on PPIs automatically when steroids are prescribed, it is reasonable to periodically reassess whether a PPI is truly needed or whether an alternative agent could be used instead.
As always, patients should not stop prescribed medications without discussing it with their medical team.